Tirzepatide is a once‐weekly dual glucose‐dependent insulinotropic polypeptide (GIP) and GLP‐1 receptor agonist, approved for the treatment of adults with type 2 diabetes (T2D), for weight management in adults with obesity or overweight with at least one weight‐related comorbid condition, and for obstructive sleep apnoea in adults with obesity.5, 6, 7. Here, GIP is linked to type 2 diabetes mellitus.